Related Experiment Video

Updated: Jun 8, 2025

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
00:05

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.2K

Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities

Xia-Wen Dang1, Ji-Long Duan1, Emily Ye2

  • 1School of Pharmacy, Key Laboratory of Elemene Class Anticancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.

Bioorganic Chemistry
|November 4, 2024
PubMed

Insights

Proto-oncogene tyrosine-protein kinase Src (c-Src) is vital in cell functions and cancer. This review details c-Src inhibitors, covering their action, discovery, combination therapy, and clinical progress.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Proto-oncogene tyrosine-protein kinase Src (c-Src) is a non-receptor tyrosine kinase crucial for cellular processes like division, motility, adhesion, and survival.
  • c-Src signaling pathways are implicated in normal cell function and cancer progression, as well as in bone loss diseases such as osteoporosis.

Purpose of the Study:

  • To review recent advancements in c-Src inhibitor research.
  • To provide insights into the mechanism of action, drug discovery, combination therapy, and clinical research of c-Src inhibitors.

Main Methods:

  • Literature review of research progress on c-Src inhibitors.
  • Analysis of studies focusing on mechanism of action, drug discovery, combination therapy, and clinical trials.

Main Results:

  • Significant progress has been made in developing c-Src inhibitors, with several candidates entering clinical trials.
  • The review consolidates information on c-Src's role in various diseases and therapeutic strategies.

Conclusions:

  • c-Src inhibitors represent a promising therapeutic avenue for cancers and inflammatory bone diseases.
  • Further research and development in c-Src inhibitor programs are encouraged to expedite drug discovery.
Keywords:
C-SrcSmall-molecule inhibitorsTherapeutic utilitiesTyrosine protein kinase (TKs)

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.5K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K